Article
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
2023-05-16
Abstract excerpt
Immune checkpoint inhibitors (ICIs) are a remarkable advancement in cancer therapeutics; however, a substantial proportion of patients develop severe immune-related adverse events (irAEs). Understanding and predicting irAEs is a key to advancing precision immuno-oncology. Immune checkpoint inhibitor-mediated colitis (IMC) is a significant complication from ICI and can have life-threatening consequences. Based on c...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- a7947bfe-6596-5b7a-ba88-c834f961cc33
- DOI
- 10.1101/2023.05.15.23289680
